VolitionRX (VNRX) Corporate presentation summary

Recent achievements

• Cat paper submitted; $5M milestone payment expected if published, with Fujifilm Vet Systems launch on automated i10 platform.

• Expansion into non-sepsis disease areas, including trauma and hidradenitis suppurativa.

• Certification completed at three French hospitals; reimbursement submission in preparation.

• Co-marketing agreement in place with Hologic; larger scale programs in confidential discussions.

• Manuscripts submitted for peer review and publication; ongoing research into clinical utility and MRD.

Executive summary and business model

• Mission to save lives and improve outcomes for people and animals globally.

• Focus on cancer and sepsis diagnostics, with low-cost, platform-agnostic testing.

• $23M in licensing revenue and $1M in Q1 2026 revenue.

• Derisked R&D and commercial strategy with 49 patent families as of March 2026.

• Asset-light model with no need for proprietary machines, labs, or sales reps.

Technology and product platform

• Specializes in quantifying nucleosomes and chromatin fragments for epigenetic diagnostics.

• Tests adaptable to manual, automated, point-of-care, and lateral flow workflows.

• Powered by Nu.Q® technology, with 69 patents granted and coverage up to 2044.

• World-first isolation of 99% pure tumor-derived DNA from liquid biopsy.

• Novel biomarkers and compelling proof-of-concept clinical data for early detection and treatment monitoring.